GlassScriptPhysician profile
Edward J Novotny
NPI 1851374078
$16,037.63
in general payments reported to CMS, 2019-2025
12 companies · $57.13 in 2025
The $57.13 reported for 2025 was less than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,160 · 2020: $2,780 · 2021: $3,423 · 2022: $6,040 · 2023: $738 · 2024: $840 · 2025: $57.13.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,635.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,634.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $10,237.24 | 2020-2022 | |
| Neuropace, INC. | $1,653.23 | 2019 | |
| Zogenix INC. | $1,100.00 | 2020 | |
| Jazz Pharmaceuticals INC. | $1,071.01 | 2022-2023 | Epidiolex |
| Zimmer Biomet Holdings, INC. | $506.36 | 2019 | |
| Sk Life Science, INC. | $396.72 | 2024 | |
| Ucb, INC. | $363.18 | 2021-2023 | Fintepla |
| Cadwell Industries, INC | $306.00 | 2023-2024 | |
| Biocodex, INC. | $213.24 | 2024-2025 | |
| Pyros Pharmaceuticals, INC. | $114.20 | 2024 | Vigpoder |
| Livanova USA, INC. | $53.50 | 2023 | Vns Therapy Sentiva Model 1000 Generator |
| Medtronic, INC. | $22.95 | 2024 | Percept PC Brainsense |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Novotny listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.